Geiger Uri 4

What Happened

• Uri Geiger, a member of NeuroPace's board of directors, was granted a total of 8,258 shares on 2026-06-05. The awards consist of 2,890 shares issued directly and 5,368 shares reported as a derivative award (held through an entity). Both grants were reported at $0.00 per share (awards/compensation rather than paid purchases).

Key Details

• Transaction date: 2026-06-05; filing date: 2026-06-05 (appears timely).
• Items granted: 2,890 shares (direct award) and 5,368 shares (derivative award via entity); total = 8,258 shares. Reported price: $0.00 (no cash paid).
• Vesting: Both awards vest in twelve equal consecutive monthly installments, subject to Geiger’s continuous service through each vesting date (footnotes F1 and F3).
• Entity/control note: The 5,368 derivative shares are held by Accelmed Partners II LP; Geiger, as managing partner of the affiliated general partner (Accelmed LLC), has sole voting and dispositive power over those shares (footnote F2). Geiger is a General Partner at Accelmed LLC and a NeuroPace director.
• Shares owned after transaction: Not specified in the filing.

Context

• These are compensation awards (not open-market purchases or sales). Awards granted at $0 typically reflect equity compensation subject to vesting and do not by themselves indicate immediate buying or selling activity.
• For retail investors, vested awards can lead to future sales, but the current filing only reports the grant and the vesting schedule — no exercise or sale occurred.